Compare Gilead Sciences, Inc. (GILD) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Jumia Technologies AG - ADR — how do they compare? Gilead Sciences, Inc. trades at $133.94 (market cap $163.51B), while Jumia Technologies AG - ADR trades at $6.54 (market cap $848.39M). The key difference: Gilead Sciences, Inc. is far larger — about 192.7× Jumia Technologies AG - ADR's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| GILD | JMIA | |
|---|---|---|
Market Cap | $163.51B | $848.39M |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $14.60 |
52-Week Low | $108.22 | $4.45 |
Enterprise Value | $178.05B | $795.49M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
JMIA trades at $6.52, down 4.82% today, amid a bearish technical signal. The company reported Q1 2026 revenue growth of 39% year-over-year but missed EPS estimates, with a net income margin of -30.79%. Cash flow improved in 2025, yet profitability remains elusive with a target set for 2027. Analyst consensus is strongly bullish with 71% buy ratings, highlighting progress in African e-commerce expansion and partnerships like Starlink.
Outlook: JMIA shows operational improvements but faces significant execution risks in achieving profitability. Investment opportunity lies in market expansion and cost management, while risks include persistent losses, competitive pressures, and macroeconomic volatility in Africa. The stock's valuation at P/S of 4.17 reflects growth expectations amid high uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
